DEF: Biote Corp. 2026 Annual Meeting Proxy Statement

Biote Corp. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on May 12, 2026.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on May 12, 2026, at 10:00 a.m. Central Time.
• Stockholders will vote on the election of two Class I directors: Andrew R. Heyer and Dana Jacoby.
• Stockholders will vote on the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The record date for voting eligibility is March 23, 2026, with 32,046,352 shares of Class A common stock and 7,249,879 shares of Class V voting stock outstanding.
• The company has undergone significant leadership changes, including the appointment of Bret Christensen as CEO effective February 1, 2025, and the transition of Marc Beer to Non-Executive Chairman effective July 1, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily covers routine annual meeting administrative matters and governance disclosures following a period of significant leadership transition.

Positives

• The company has maintained compliance with its debt covenants as of December 31, 2025.
• The Board has established a clear leadership structure with a lead independent director, Richard R. Barrera, to oversee the non-independent Chairman.
• The company has successfully transitioned to a new CEO, Bret Christensen, who brings extensive experience in the healthcare sector.

Negatives

• The company experienced past events of default under its credit agreement in 2023 and 2024, though these were subsequently waived.
• The company has seen significant turnover in executive leadership, including the resignation of the former CEO and the departure of the former General Counsel.
• The company's former CEO and founder, Dr. Gary Donovitz, required a substantial settlement agreement involving the repurchase of shares for approximately $76.9 million.

Risks

• The company's reliance on key personnel and the potential for further leadership instability.
• Potential for future defaults under credit agreements if financial covenants or reporting requirements are not met.
• The company is an emerging growth company, which may result in less comprehensive financial disclosure compared to larger, more established public companies.
• The company's business is subject to regulatory and compliance risks inherent in the healthcare industry.

Future Outlook

The company continues to focus on its strategic goals and leadership transition, with management emphasizing the importance of long-term stockholder value and operational efficiency.

Management Comments

• The Board believes that holding the Annual Meeting in a virtual format enables increased stockholder attendance and participation.
• The Board believes that retaining flexibility in the leadership structure is in the best interests of the Company and its stockholders.

Industry Context

StockSavvy.ai notes that Biote's transition to a virtual-only annual meeting format is consistent with broader trends among mid-cap healthcare companies seeking to reduce costs and increase accessibility for a geographically dispersed shareholder base.

Comparison to Industry Standards

• The company's executive compensation structure, including the use of stock options and performance-based bonuses, is generally aligned with standard practices for emerging growth companies in the healthcare sector.
• The use of a lead independent director to balance a non-independent Chairman is a standard corporate governance practice for companies transitioning from founder-led management.

Management Changes

Corporate Governance

Legal Proceedings

• The company entered into a settlement agreement with its founder, Dr. Gary Donovitz, which included the repurchase of shares and the termination of the Founder Advisory Agreement.

Related Party Transactions

• The company has entered into various agreements with related parties, including the Tax Receivable Agreement and the A&R Investor Rights Agreement, as disclosed in the filing.

Stakeholder Impact

• Shareholders are requested to vote on director elections and auditor ratification.
• The company's leadership changes and settlement agreements have significant implications for capital structure and cash flow.

Next Steps

• Stockholders are encouraged to vote their shares via the Internet, telephone, or mail prior to the Annual Meeting.
• The company will hold the virtual Annual Meeting on May 12, 2026.
• Final voting results will be published in a Form 8-K within four business days after the meeting.

Key Dates

Keywords

Biote Corp, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Healthcare, SEC Filing